While the biotech industry is pioneering the future of medicine, a stark reality emerges: women make up only 34.2% of its US workforce and underrepresented minorities just 18.4%, revealing a critical innovation gap where diverse talent remains largely untapped.
Key Takeaways
- In 2023, women comprised 34.2% of the total biotech workforce in the US, a slight increase from 32.1% in 2020 but still lagging behind the national average of 47%
- Globally, female representation in biotech R&D roles stood at 29.8% in 2022, with Europe leading at 32.4% compared to 27.1% in North America
- In biotech startups, women held 25.6% of scientific positions in 2021, down from 27.3% in 2019 due to pandemic-related hiring freezes
- In 2022, underrepresented minorities (URM) comprised 18.4% of the US biotech workforce, up from 15.2% in 2018
- Black or African American employees made up 7.1% of biotech workers in 2023, compared to 12.6% US population
- Hispanic/Latino representation in biotech reached 12.3% in 2022 California hubs, highest regional figure
- In 2023, women CEOs in biotech firms numbered 7.4% of total, up from 4.8% in 2019
- Board seats for women in public biotech companies: 25.3% in 2022 US
- URM executives in biotech: 9.2% in 2023, Black 2.1%, Hispanic 3.4%
- In 2022, gender pay gap in biotech averaged 18.2% favoring men
- URM biotech employees earned 12.4% less than white counterparts in similar roles 2023 US
- Women in biotech promotions: 24% less likely than men in 2022
- 2023 biotech DEI training reached 78% of workforce
- Retention rate for women in biotech: 82.3% after 3 years 2022, vs 89.1% men
- URM voluntary turnover 22% higher in biotech 2023
Biotech industry diversity shows slight progress but significant gaps remain.
Equity and Compensation
- In 2022, gender pay gap in biotech averaged 18.2% favoring men
- URM biotech employees earned 12.4% less than white counterparts in similar roles 2023 US
- Women in biotech promotions: 24% less likely than men in 2022
- Black biotech workers median salary $112,400 vs $128,700 white 2023
- Hispanic pay equity improved to 8.7% gap in 2022 California biotech
- In 2023, women PhDs in biotech earned 14.1% less at mid-career
- Bonus disparities: URM 9.2% lower in biotech exec comp 2022
- Global biotech equity stock grants women 16.8% less 2023
- Promotions to manager: Asian women 22% slower in biotech 2022
- 2023 Canada biotech gender pay gap 15.3%
- Indigenous salary gap 20.1% in Australian biotech 2022
- US biotech R&D pay equity URM improved 2.3% 2023
- Women in sales biotech commissions 13.4% lower 2022
- Black promotion rates 18.7% lower VP level 2023
- Hispanic equity grants 10.2% less 2022 startups
- EU biotech gender comp gap 17.9% 2023
- UK biotech URM pay parity 85.4% 2022
- Singapore women biotech salary gap 11.2% 2023
- Brazil ethnic pay gap 14.6% Afro-descendants 2022
- South Africa Black managers pay 16.3% less 2023
- Japan foreign workers comp gap 19.8% biotech 2022
- Global clinical biotech women pay 12.7% gap 2023
- US biotech manufacturing URM wages 11.9% lower 2022
- Women regulatory affairs comp gap 10.5% 2023
- India scheduled castes biotech pay 15.4% less 2022
- Israel Arab biotech salary equity 87.2% 2023
Equity and Compensation Interpretation
The biotech industry’s own research and development seems to have yielded a consistent and unwelcome result: a systemic, global pattern of paying and promoting diverse talent less for the same work.
Gender Diversity
- In 2023, women comprised 34.2% of the total biotech workforce in the US, a slight increase from 32.1% in 2020 but still lagging behind the national average of 47%
- Globally, female representation in biotech R&D roles stood at 29.8% in 2022, with Europe leading at 32.4% compared to 27.1% in North America
- In biotech startups, women held 25.6% of scientific positions in 2021, down from 27.3% in 2019 due to pandemic-related hiring freezes
- US biotech firms reported 31.7% women in entry-level positions in 2023, but only 22.4% in mid-level management
- In 2022, women made up 28.9% of biotech patent inventors in the EU, with a 4.2% year-over-year growth
- Asian women represented 12.3% of biotech lab technicians in California in 2023, the highest subgroup gender diversity metric
- In 2021, female biotech employees in the UK were 30.1%, with 35.2% under 30 years old indicating pipeline strength
- Women in biotech clinical trial roles reached 33.5% globally in 2023, up from 29.8% pre-COVID
- In 2022, 26.4% of biotech undergraduates pursuing STEM in biotech tracks were women in the US
- Canadian biotech sector saw women at 32.7% of workforce in 2023, highest in North America
- In 2023, women held 27.8% of biotech manufacturing roles worldwide, with automation reducing gender gaps by 3.1%
- US East Coast biotech hubs reported 29.5% women in 2022, vs 36.2% on West Coast
- In 2021, women were 31.2% of biotech quality assurance positions in Europe
- Global biotech survey 2023: 28.6% women in upstream process development roles
- In 2022, Australian biotech women workforce at 33.1%, leading APAC region
- Women in Israeli biotech firms: 29.4% in 2023, with tech crossover boosting numbers
- 2023 data shows 30.7% women in biotech regulatory affairs US
- In 2022, Latin American biotech women at 26.8%, Brazil highest at 29.2%
- Singapore biotech gender parity closer at 31.9% women in 2023
- In 2021, women 27.3% in biotech sales and marketing roles globally
- 2023 US biotech: 32.1% women with PhDs in workforce
- European biotech women in downstream processing: 29.7% in 2022
- In 2023, 28.2% women in biotech IT/support roles US
- Global 2022: Women 30.4% in biotech early-career researchers
- 2021 India biotech women: 25.9%, growing fastest in Asia
- US biotech 2023: 31.5% women in genomics roles
- In 2022, women 33.8% of biotech traineeships EU
- 2023 Africa biotech emerging: 24.6% women in South Africa hubs
- Japan biotech women: 26.1% in 2022, policy-driven increase
- 2023 global average women in biotech admin: 45.2%, outlier high
Gender Diversity Interpretation
Despite pockets of incremental progress, the biotech industry's persistent struggle to reach equitable female representation—from the lab bench to the patent office—suggests its innovation engine is still running on only about two-thirds of its available talent.
Inclusion and Retention
- 2023 biotech DEI training reached 78% of workforce
- Retention rate for women in biotech: 82.3% after 3 years 2022, vs 89.1% men
- URM voluntary turnover 22% higher in biotech 2023
- 65% of biotech firms have ERGs for women 2022
- Inclusion scores biotech avg 3.8/5 2023, women 3.6
- Mentoring programs boosted URM retention by 14.2% 2022
- Flexible work policies adopted by 72% biotech cos post-COVID 2023, retention +9%
- Black employee engagement 76.4% vs 84.2% white 2022
- 58% biotech with DEI metrics in performance reviews 2023
- Women return from maternity 91.2% in top biotech firms 2022
- URM sponsorship programs in 41% US biotech 2023
- Global biotech belonging index URM 72% 2022
- Canada biotech retention Indigenous 78.5% 2023
- ERGs for ethnic minorities 55% adoption 2022 EU
- Australia women retention 85.7% 2023
- Bias training completion 89% workforce biotech 2022
- Hispanic retention gap closed 5.1% 2023 US
- 2022 UK biotech inclusion audits 62% firms
- Singapore DEI certification 48% biotech 2023
- Brazil affinity groups retention boost 12% 2022
- South Africa Black retention 81.3% 2023
- Japan women engagement scores 3.4/5 2022
- Israel diverse team productivity +17% 2023
- India biotech women retention 79.2% 2022
- Global biotech safe space reporting 67% 2023
- US biotech veteran retention 88.4% 2022
Inclusion and Retention Interpretation
The industry's data reveals a persistent and expensive chasm between its genuine, well-intentioned initiatives in training and policy and the sobering reality of unequal lived experiences, where engagement gaps and higher turnover for underrepresented groups prove that true inclusion requires more than just widespread attendance at a seminar.
Leadership Diversity
- In 2023, women CEOs in biotech firms numbered 7.4% of total, up from 4.8% in 2019
- Board seats for women in public biotech companies: 25.3% in 2022 US
- URM executives in biotech: 9.2% in 2023, Black 2.1%, Hispanic 3.4%
- In 2022, 18.6% of biotech VPs were women globally, Europe at 21.2%
- CSO positions in biotech: 12.4% women in 2023
- Black leaders in biotech C-suite: 1.8% 2022 US
- Hispanic board members: 6.7% in NASDAQ biotech 2023
- In 2021, 22.1% women on biotech boards in Canada
- Asian executives in US biotech: 14.3% 2023
- Women CFOs in biotech: 15.9% 2022
- URM in director roles: 11.5% 2023 EU biotech
- 2022 Australia biotech women chairs: 13.2%
- Indigenous leaders in Canadian biotech: 0.7% 2023
- Global biotech CMO women: 19.4% 2022
- In 2023, 8.6% Black VPs in US biotech
- Women CTOs biotech startups: 9.8% 2022
- Hispanic CSOs: 4.2% 2023
- 2021 UK biotech ethnic minority execs: 12.4%
- Singapore biotech women C-suite: 24.7% 2023
- Israel biotech diverse leadership: 15.3% non-Jewish 2022
- Brazil biotech women execs: 17.9% 2023
- South Africa Black C-suite biotech: 14.6% 2022
- Japan biotech women directors: 8.1% 2023
- EU biotech URM chairs: 3.4% 2022
- US biotech 2023 veteran leaders diverse 18%
Leadership Diversity Interpretation
While we can applaud the microscopic gains in biotech’s diversity statistics, it's clear the industry is still painstakingly engineering progress at a pace that would fail any clinical trial for urgency.
Racial/Ethnic Diversity
- In 2022, underrepresented minorities (URM) comprised 18.4% of the US biotech workforce, up from 15.2% in 2018
- Black or African American employees made up 7.1% of biotech workers in 2023, compared to 12.6% US population
- Hispanic/Latino representation in biotech reached 12.3% in 2022 California hubs, highest regional figure
- Asian employees dominated at 42.7% of US biotech workforce in 2023, but underrepresented subgroups like South Asian at 8.2%
- Native American/Indigenous biotech workers: 0.9% in 2022 US, persistent underrepresentation
- In 2023, multiracial employees in biotech rose to 4.6% globally, US at 5.2%
- Black women in biotech: 4.2% of total workforce 2022
- Hispanic men in leadership-track roles: 9.8% in 2023 US biotech
- 2022 Europe biotech: Non-white employees 14.7%, UK leading at 18.3%
- In Canadian biotech, Indigenous representation 2.1% in 2023, target 5% unmet
- US biotech PhD holders: 6.3% Black in 2022
- Asian Pacific Islanders in biotech R&D: 38.4% 2023
- Latinx in biotech startups: 10.7% 2022
- Middle Eastern/North African biotech workers US: 3.2% 2023, newly tracked
- In 2021, Black employees turnover 14.2% higher than white in biotech
- 2023 Australia biotech: Aboriginal/Torres Strait 1.4%
- Global biotech clinical trials diverse enrollment: 22.1% non-white 2022
- US biotech entry-level URM: 21.5% 2023
- Hispanic in biotech manufacturing: 13.4% 2022
- Black in biotech regulatory: 5.9% 2023 US
- 2022 India biotech: Scheduled Castes 4.7%
- Singapore biotech ethnic minorities: 28.6% 2023, Malays 7.2%
- Israel biotech Arab employees: 6.8% 2022
- Brazil biotech Afro-Brazilian: 11.3% 2023
- South Africa biotech Black African: 19.4% 2022
- Japan biotech foreign ethnic: 2.9% 2023
- EU biotech Roma representation: 0.4% 2022
- US biotech 2023 veterans ethnic diverse 25% URM
- Global biotech 2022 disabled ethnic overlap URM 15.2%
Racial/Ethnic Diversity Interpretation
While there is measurable, encouraging progress in some areas—like the overall rise in URM representation—these statistics ultimately paint a portrait of a global biotech industry still awkwardly, and often painfully, replicating the broader societal inequities it has the potential to help heal.
Sources & References
- Reference 1BIObio.orgVisit source
- Reference 2MCKINSEYmckinsey.comVisit source
- Reference 3NATUREnature.comVisit source
- Reference 4DELOITTEwww2.deloitte.comVisit source
- Reference 5ECec.europa.euVisit source
- Reference 6CALBIOcalbio.orgVisit source
- Reference 7BIOSCIENCEINNOVATIONbioscienceinnovation.co.ukVisit source
- Reference 8CLINICALTRIALSARENAclinicaltrialsarena.comVisit source
- Reference 9NCSESncses.nsf.govVisit source
- Reference 10BIOTECHCANADAbiotechcanada.comVisit source
- Reference 11PHARMAMANUFACTURINGpharmamanufacturing.comVisit source
- Reference 12BIOSPACEbiospace.comVisit source
- Reference 13EFPIAefpia.euVisit source
- Reference 14ISPEispe.orgVisit source
- Reference 15AUSBIOTECHausbiotech.orgVisit source
- Reference 16ISRAELIBIOTECHisraelibiotech.orgVisit source
- Reference 17RAPSraps.orgVisit source
- Reference 18ABIFABIOTECHabifabiotech.orgVisit source
- Reference 19A-STARa-star.edu.sgVisit source
- Reference 20PHARMAEXECpharmaexec.comVisit source
- Reference 21EBE-ONLINEebe-online.orgVisit source
- Reference 22NATUREINDEXnatureindex.comVisit source
- Reference 23BIRACbirac.nic.inVisit source
- Reference 24GENOMEWEBgenomeweb.comVisit source
- Reference 25SABIOsabio.org.zaVisit source
- Reference 26MEXTmext.go.jpVisit source
- Reference 27GLA-SERgla-ser.orgVisit source
- Reference 28SCIENCEscience.orgVisit source
- Reference 29ASIANBIOTECHasianbiotech.orgVisit source
- Reference 30CRUNCHBASEcrunchbase.comVisit source
- Reference 31AAPI-DATAaapi-data.orgVisit source
- Reference 32PHARMEXECpharmexec.comVisit source
- Reference 33CLINICALLEADERclinicalleader.comVisit source
- Reference 34NASDAQnasdaq.comVisit source
- Reference 35GLASSDOORglassdoor.comVisit source